Association of stent thrombectomy and conventional treatment with neuroprotection, complications, anxiety, and depression in acute ischemic stroke patients

Table 1 NIHSS score and Barthel index score (n = 45), mean ± SD

Group	NIHSS scoring		Barthel index score
	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment
Observation group	13.42 ± 3.71	4.08 ± 2.81a	27.04 ± 9.92	59.83 ± 11.45a
Control group	12.84 ± 3.61	8.14 ± 3.24b	27.41 ± 10.04	45.25 ± 12.08b
t value	0.752	6.350	0.176	5.876
P value	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05 vs the observation group before treatment.

^bP < 0.05 vs the control group before treatment.

NIHSS: National Institutes of Health Stroke Scale.

Table 2 Hamilton Anxiety Scale and Hamilton Depression Scale score of the patients (n = 45), mean ± SD

Group	HAMA		HAMD
	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment
Observation group	20.80 ± 1.70	8.84 ± 1.22a	11.20 ± 1.34	5.27 ± 0.69a
Control group	20.31 ± 2.16	12.69 ± 1.22b	11.69 ± 1.40	7.71 ± 0.66b
t value	1.196	2.103	1.696	17.142
P value	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05 vs the observation group before treatment.

^bP < 0.05 vs the control group before treatment.

HAMA: Hamilton Anxiety Scale; HAMD: Hamilton Depression Scale.

Table 3 Blood lipids, inflammatory factors and plaque area before and after treatment (n = 45), mean ± SD

Group	TC (mmol/L)		TG (mmol/L)		CRP (mg/L)		Patch area (mm2)
	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment
Observation group	5.73 ± 0.42	3.42 ± 0.21a	1.89 ± 0.62	1.43 ± 0.15a	8.45 ± 1.35	4.52 ± 1.56a	26.54 ± 10.38	19.52 ± 7.35a
Control group	5.81 ± 0.53	4.25 ± 0.25b	1.93 ± 0.57	1.08 ± 0.12b	8.38 ± 1.61	3.14 ± 1.37b	27.12 ± 10.45	24.56 ± 7.01b
t value	0.794	17.053	0.319	12.223	0.223	4.459	0.264	3.329
P value	> 0.05	< 0.05	> 0.05	< 0.05	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05 vs the observation group before treatment.

^bP < 0.05 vs the control group before treatment.

TC: Total cholesterol; TG: Triglyceride; CRP: C-reactive protein.

Table 4 Smur100 β protein, neuron-specific enolase and homocysteine levels before and after treatment (n = 45), mean ± SD

Group	NSE (μg/L)		S-100β (μg/L)		Hcy (μmol/L)
	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment
Observation group	14.35 ± 2.09	6.73 ± 1.25a	1.54 ± 0.35	0.31 ± 0.09a	31.54 ± 5.29	17.24 ± 3.51a
Control group	14.25 ± 2.24	8.56 ± 1.44b	1.38 ± 0.47	0.74 ± 0.19b	30.89 ± 5.47	21.73 ± 4.88b
t value	0.219	6.438	1.832	13.720	0.573	5.011
P value	> 0.05	< 0.05	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05 vs the observation group before treatment.

^bP < 0.05 vs the control group before treatment.

NSE: Neuron-specific enolase; Hcy: Homocysteine.

Table 5 The vascular endothelial function before and after treatment in patients (n = 45), mean ± SD

Group	VEGF (ng/L)		NOS (ng/L)		ET-1 (U/mL)
	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment	Before treatment	After 8 weeks of treatment
Observation group	298.54 ± 35.25	418.84 ± 42.15a	24.84 ± 6.15	37.98 ± 6.41a	91.58 ± 7.54	50.65 ± 5.48a
Control group	297.73 ± 34.91	315.24 ± 39.58b	24.75 ± 6.48	25.44 ± 6.05b	92.05 ± 8.01	64.25 ± 6.51b
t value	0.110	12.019	0.068	9.544	0.287	10.721
P value	> 0.05	< 0.05	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05 vs the observation group before treatment.

^bP < 0.05 vs the control group before treatment.

VEGF: Vascular endothelial growth factor; NOS: Nitric oxide synthase; ET-1: Endothelin-1.

Table 6 The incidence of complications, n (%)

Group	n	Vascular re-occlusion	Brain edema	Reperfusion injury	Intracranial hemorrhage	Secondary hemorrhage of infarct focus	Total incidence rate
Observation group	45	1 (2.22)	2 (4.44)	0 (0.00)	1 (2.22)	0 (0.00)	4 (8.88)
Control group	45	4 (8.88)	3 (6.67)	2 (4.44)	4 (8.88)	2 (4.44)	15 (33.33)
χ² value							8.073
P value							< 0.05